As part of our ‘Korea and Coronavirus Series,’ The Korea Society will again host a conversation with Dr. Jerome Kim, Director General of International Vaccine Institute (IVI) and Tom Byrne, The Korea Society’s President/CEO. Dr. Manki Song, Deputy Director General of IVI will also join the interview. The speakers will focus on South Korea’s efforts on becoming a ‘K -Global Vaccine Hub,’ a new initiative to strengthen vaccine capabilities on COVID-19 as well as future pandemics. They will also highlight IVI’s continuous journey on overcoming the pandemic and its future plans on building public safety. This program will be recorded at IVI in Seoul when President Byrne visits South Korea in late June.

K-Global Vaccine Hub
with
Dr. Jerome Kim and Dr. Manki Song

Premieres: Wednesday, July 13, 2022 at 6:30 PM (EDT)

The Korea Society
350 Madison Avenue, 24th Floor
New York, NY 10017

ABOUT THE SPEAKERS



Dr. Jerome H. Kim
Director General
International Vaccine Institute

Jerome H. Kim, M.D., is an international expert on the development and evaluation of vaccines and is the Director General of the International Vaccine Institute (IVI), whose mission is to discover, develop and deliver safe, effective and affordable vaccines for Global Health. IVI’s oral cholera vaccine is used around the world to prevent this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma, is in Phase III testing with regulatory approval expected in 2022. IVI's work with companies developing COVID-19 vaccines may contribute 1.2 billion doses to the global COVAX facility – providing COVID-19 vaccines for people in low and middle income countries. Prior to IVI, he was the Principal Deputy, US Military HIV Research Program and Chief, Laboratory of Molecular Virology and Pathogenesis at the Walter Reed Army Institute of Research, and the US Army Program Manager for HIV Vaccines. He led the Army’s RV144 Phase III HIV vaccine trial that showed efficacy in the prevention of HIV-1. Dr. Kim is an Adjunct Professor, Department of Medicine, Uniformed Services University and at the Graduate School of Public Health, Yonsei University. He has authored over 300 publications. He is a graduate of the University of Hawaii, with high honors in History and highest honors in Biology and received his M.D. from the Yale University School of Medicine. Dr. Kim has received numerous awards: John Maher Award for Research Excellence, USUHS, 2013; Department of the Army Research and Development Achievement Award for Technical Excellence, 2013; Asia Pacific Vaccine Excellence Lifetime Achievement Award, 2021; Medal of Honor for Civil Merit from the Republic of Korea’s government, 2022.






Dr. Manki Song
Deputy Director General
International Vaccine Institute

Manki Song, Ph.D., joined the International Vaccine Institute (IVI) as a research scientist on July 01, 2004. He acquired B.S. degree from Seoul National University in 1992, and M.S. and Ph.D. degrees in Viral Immunology under Prof. Young-Chul Sung from Pohang University of Science and Technology (POSTECH). He continued postdoctoral work at POSTECH on the development of HBV and HCV vaccines. In 2001, he was appointed as an IVI postdoctoral fellow and seconded to Prof. Myron Levine’s Center for Vaccine Development (CVD) at the University of Maryland School of Medicine in Baltimore, USA. During this 2-year training period, he focused on the development of a new generation measles vaccine using naked DNA, and attenuated Shigella and Salmonella vaccines.

He had a longstanding interest in public health and threats to the health of developing country populations. In the early part of his career, he focused on the study of viral diseases, particularly HIV, HCV and tuberculosis. Most recently, as the Head of Clinical Research Laboratory Department at IVI, he had the opportunity to expand the scope of research to engage in the development of vaccines against the norovirus, HAV, SFTS and MERS-CoV. Recently, Dr. Song lead a collaborative study to establish international standard material and assay for MERS-CoV, collaboration with National Institute for Biological Standards and Control (NIBSC) funded by Coalition for Epidemic Preparedness Innovations (CEPI).

* Publications: https://www.ncbi.nlm.nih.gov/myncbi/1d1CyzcGyleEuo/bibliography/public/